Celldex Therapeutics CLDX Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Celldex Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Celldex Therapeutics's cash ratio?
- Celldex Therapeutics (CLDX) reported cash ratio of 0.7× in Q1 2026.
- How has Celldex Therapeutics's cash ratio changed year-over-year?
- Celldex Therapeutics's cash ratio increased by 29.7% year-over-year, from 0.5× to 0.7×.
- What is the long-term trend for Celldex Therapeutics's cash ratio?
- Over 5 years (2020 to 2025), Celldex Therapeutics's cash ratio has grown at a -28.8% compound annual growth rate (CAGR), from 3.1× to 0.6×.
- What does cash ratio mean?
- Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.